Switch theme
Sign up to access all valuation multiples
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
1983
140
LTM Revenue $1.2M
LTM EBITDA -$88.0M
-$17.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Perspective Therapeutics has a last 12-month revenue (LTM) of $1.2M and a last 12-month EBITDA of -$88.0M.
In the most recent fiscal year, Perspective Therapeutics achieved revenue of n/a and an EBITDA of -$78.1M.
Perspective Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Perspective Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $1.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$88.0M | XXX | -$78.1M | XXX | XXX | XXX |
| EBITDA Margin | -7165% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$93.5M | XXX | -$66.8M | XXX | XXX | XXX |
| EBIT Margin | -7619% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$83.1M | XXX | -$79.3M | XXX | XXX | XXX |
| Net Margin | -6768% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Perspective Therapeutics's stock price is $3.
Perspective Therapeutics has current market cap of $191M, and EV of -$17.1M.
See Perspective Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$17.1M | $191M | XXX | XXX | XXX | XXX | $-1.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Perspective Therapeutics has market cap of $191M and EV of -$17.1M.
Perspective Therapeutics's trades at n/a EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Perspective Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Perspective Therapeutics has a P/E ratio of -2.3x.
See valuation multiples for Perspective Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $191M | XXX | $191M | XXX | XXX | XXX |
| EV (current) | -$17.1M | XXX | -$17.1M | XXX | XXX | XXX |
| EV/Revenue | -13.9x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.3x | XXX | XXX | XXX |
| EV/Gross Profit | -13.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.3x | XXX | -2.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPerspective Therapeutics's last 12 month revenue growth is -22%
Perspective Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Perspective Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Perspective Therapeutics's rule of X is -7220% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Perspective Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -22% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -7165% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 49% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -7220% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| Senseonics Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Perspective Therapeutics acquired XXX companies to date.
Last acquisition by Perspective Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Perspective Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Perspective Therapeutics founded? | Perspective Therapeutics was founded in 1983. |
| Where is Perspective Therapeutics headquartered? | Perspective Therapeutics is headquartered in United States of America. |
| How many employees does Perspective Therapeutics have? | As of today, Perspective Therapeutics has 140 employees. |
| Who is the CEO of Perspective Therapeutics? | Perspective Therapeutics's CEO is Mr. Johan M. Spoor. |
| Is Perspective Therapeutics publicy listed? | Yes, Perspective Therapeutics is a public company listed on ASE. |
| What is the stock symbol of Perspective Therapeutics? | Perspective Therapeutics trades under CATX ticker. |
| When did Perspective Therapeutics go public? | Perspective Therapeutics went public in 2005. |
| Who are competitors of Perspective Therapeutics? | Similar companies to Perspective Therapeutics include e.g. Philips, SmartVest, InfuSystem, Myomo. |
| What is the current market cap of Perspective Therapeutics? | Perspective Therapeutics's current market cap is $191M |
| What is the current revenue of Perspective Therapeutics? | Perspective Therapeutics's last 12 months revenue is $1.2M. |
| What is the current revenue growth of Perspective Therapeutics? | Perspective Therapeutics revenue growth (NTM/LTM) is -22%. |
| What is the current EV/Revenue multiple of Perspective Therapeutics? | Current revenue multiple of Perspective Therapeutics is -13.9x. |
| Is Perspective Therapeutics profitable? | Yes, Perspective Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Perspective Therapeutics? | Perspective Therapeutics's last 12 months EBITDA is -$88.0M. |
| What is Perspective Therapeutics's EBITDA margin? | Perspective Therapeutics's last 12 months EBITDA margin is -7165%. |
| What is the current EV/EBITDA multiple of Perspective Therapeutics? | Current EBITDA multiple of Perspective Therapeutics is 0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
